AstraZeneca_NNP Annual_JJ Report_NNP and_CC Additional_JJ Information_NN 140_CD Form_NN 20-F_JJ Information_NN 2003_CD Additional_JJ Information_NN History_NN and_CC development_NN of_IN the_DT Company_NN Directors_NNS are_VBP not_RB required_VBN to_TO retire_VB at_IN a_DT shareholders_NNS ._.
All_DT other_JJ extraordinary_JJ general_JJ AstraZeneca_NNP PLC_NNP was_VBD incorporated_VBN in_IN particular_JJ age_NN ._.
meetings_NNS require_VBP 14_CD clear_JJ days_NNS notice_NN ._.
England_NNP and_CC Wales_NNP on_IN 17_CD June_NNP 1992_CD under_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
It_PRP is_VBZ a_DT public_JJ limited_JJ Directors_NNS are_VBP required_VBN to_TO beneficially_RB own_VB For_IN all_DT general_JJ meetings_NNS ,_, a_DT quorum_NN of_IN two_CD company_NN domiciled_VBD in_IN the_DT UK_NNP ._.
The_DT Ordinary_NNP Shares_NNP in_IN the_DT Company_NN of_IN an_DT shareholders_NNS present_VBP in_IN person_NN or_CC by_IN proxy_NN Companys_NNP registered_VBD number_NN is_VBZ 2723534_CD aggregate_JJ nominal_JJ amount_NN of_IN $_$ 125_CD ._.
and_CC its_PRP$ registered_JJ office_NN is_VBZ at_IN 15_CD Stanhope_NNP present_NN ,_, this_DT means_VBZ they_PRP must_MD own_VB at_IN least_JJS Gate_NN ,_, London_NNP W1K_NNP 1LN_NNP telephone_NN 44_CD 500_CD shares_NNS ._.
Shareholders_NNS and_CC their_PRP$ duly_RB appointed_VBN 0_CD 20 7304 5000_CD ._.
From_IN February_NNP 1993_CD until_IN proxies_NNS and_CC corporate_JJ representatives_NNS are_VBP April_NNP 1999_CD ,_, the_DT Company_NN was_VBD called_VBN Zeneca_NNP Rights_NNPS ,_, preferences_NNS and_CC restrictions_NNS entitled_VBN to_TO be_VB admitted_VBN to_TO general_JJ meetings_NNS ._.
On_IN 6_CD April_NNP 1999_CD ,_, the_DT Company_NN attaching_VBG to_TO shares_NNS changed_VBD its_PRP$ name_NN to_TO AstraZeneca_NNP PLC._NNP ._.
The_DT share_NN capital_NN of_IN the_DT Company_NN is_VBZ divided_VBN Limitations_NNPS on_IN the_DT rights_NNS to_TO own_VB shares_NNS into_IN 2,400,000,000_CD Ordinary_NNP Shares_NNP with_IN a_DT There_EX are_VBP no_DT limitations_NNS on_IN the_DT rights_NNS to_TO own_VB The_DT Company_NN was_VBD formed_VBN when_WRB the_DT nominal_JJ value_NN of_IN $_$ 0.25_CD each_DT and_CC 50,000_CD shares_NNS ._.
pharmaceutical_JJ ,_, agrochemical_NN and_CC specialty_NN Redeemable_JJ Preference_NN Shares_NNS with_IN a_DT chemical_NN businesses_NNS of_IN Imperial_NNP Chemical_NNP nominal_JJ value_NN of_IN 1.00_CD each_DT ._.
The_DT rights_NNS and_CC Industries_NNP PLC_NNP were_VBD demerged_VBN in_IN 1993_CD ._.
In_IN restrictions_NNS attaching_VBG to_TO the_DT Redeemable_JJ 1999_CD ,_, the_DT Company_NN sold_VBD the_DT specialty_NN Preference_NNP Shares_NNP differ_VBP from_IN those_DT attaching_VBG chemical_NN business_NN ._.
Also_RB in_IN 1999_CD ,_, the_DT to_TO Ordinary_NNP Shares_NNP as_IN follows_VBZ :_: Company_NN merged_VBD with_IN Astra_NNP AB_NNP of_IN Sweden_NNP ._.
In_IN 2000_CD ,_, it_PRP demerged_VBD the_DT agrochemical_NN the_DT Redeemable_NNP Preference_NNP Shares_NNP carry_VBP business_NN and_CC merged_VBD it_PRP with_IN the_DT similar_JJ no_DT rights_NNS to_TO receive_VB dividends_NNS :_: agribusiness_NN of_IN Novartis_NNP AG_NNP to_TO form_VB a_DT new_JJ company_NN called_VBD Syngenta_NNP AG_NNP ._.
the_DT holders_NNS of_IN Redeemable_JJ Preference_NN Shares_NNS have_VBP no_DT rights_NNS to_TO receive_VB notices_NNS The_DT Company_NN owns_VBZ and_CC operates_VBZ numerous_JJ of_IN ,_, attend_VB or_CC vote_VB at_IN general_JJ meetings_NNS R&D_NNP ,_, production_NN and_CC marketing_NN facilities_NNS except_IN in_IN certain_JJ limited_JJ circumstances_NNS :_: worldwide_NN ._.
Its_PRP$ corporate_JJ headquarters_NNS are_VBP at_IN they_PRP have_VBP one_CD vote_NN for_IN every_DT 50,000_CD 15_CD Stanhope_NNP Gate_NNP ,_, London_NNP W1K_NNP 1LN_NNP and_CC its_PRP$ Redeemable_JJ Preference_NNP Shares_NNP held_VBD :_: R&D_NNP headquarters_NNS are_VBP at_IN SE-151_CD 85_CD Sdertlje_NNP ,_, Sweden_NNP ._.
on_IN a_DT distribution_NN of_IN assets_NNS of_IN the_DT Company_NN ,_, on_IN a_DT winding-up_NN or_CC other_JJ Memorandum_NNP and_CC Articles_NNPS of_IN Association_NNP return_NN of_IN capital_NN subject_NN to_TO certain_JJ Objects_NNS exceptions_NNS ,_, the_DT holders_NNS of_IN Redeemable_JJ As_IN is_VBZ typical_JJ of_IN companies_NNS registered_VBN in_IN Preference_NNP Shares_NNP have_VBP priority_NN over_IN the_DT England_NNP and_CC Wales_NNP ,_, the_DT Companys_NNP objects_NNS ,_, holders_NNS of_IN Ordinary_NNP Shares_NNP to_TO receive_VB the_DT which_WDT are_VBP detailed_VBN in_IN the_DT Memorandum_NNP of_IN capital_NN paid_VBN up_RP on_IN those_DT shares_NNS :_: and_CC Association_NNP ,_, are_VBP broad_JJ and_CC wide-ranging_JJ and_CC include_VBP manufacturing_NN ,_, distributing_VBG and_CC subject_JJ to_TO the_DT provisions_NNS of_IN the_DT trading_NN pharmaceutical_JJ products_NNS ._.
Companies_NNS Act_NNP 1985_CD ,_, the_DT Company_NN has_VBZ the_DT right_NN to_TO redeem_VB the_DT Redeemable_JJ Directors_NNS Preference_NNP Shares_NNP at_IN any_DT time_NN on_IN giving_VBG Subject_NNP to_TO certain_JJ exceptions_NNS ,_, Directors_NNS do_VBP not_RB less_JJR than_IN seven_CD days_NNS written_VBN notice_NN ._.
not_RB have_VB power_NN to_TO vote_VB at_IN Board_NNP Meetings_NNS on_IN matters_NNS in_IN which_WDT they_PRP have_VBP a_DT material_NN Action_NNP necessary_JJ to_TO change_VB the_DT rights_NNS of_IN interest_NN ._.
shareholders_NNS In_IN order_NN to_TO vary_VB the_DT rights_NNS attached_VBN to_TO any_DT The_DT quorum_NN for_IN meetings_NNS of_IN the_DT Board_NNP of_IN class_NN of_IN shares_NNS ,_, the_DT consent_NN in_IN writing_NN of_IN the_DT Directors_NNS is_VBZ a_DT majority_NN of_IN the_DT full_JJ Board_NNP ,_, of_IN holders_NNS of_IN three_CD quarters_NNS in_IN nominal_JJ value_NN of_IN whom_WP at_IN least_JJS four_CD must_MD be_VB Non-Executive_JJ the_DT issued_VBN shares_NNS of_IN that_DT class_NN or_CC the_DT Directors_NNS ._.
In_IN the_DT absence_NN of_IN a_DT quorum_NN ,_, the_DT sanction_NN of_IN an_DT extraordinary_JJ resolution_NN Directors_NNS do_VBP not_RB have_VB power_NN to_TO determine_VB passed_VBN at_IN a_DT general_JJ meeting_NN of_IN such_JJ holders_NNS compensation_NN arrangements_NNS for_IN themselves_PRP is_VBZ required_VBN ._.
or_CC any_DT member_NN of_IN the_DT Board_NNP ._.
Annual_JJ general_JJ meetings_NNS and_CC The_DT Board_NNP of_IN Directors_NNS may_MD exercise_VB all_PDT the_DT extraordinary_JJ general_JJ meetings_NNS powers_NNS of_IN the_DT Company_NN to_TO borrow_VB money_NN ._.
Annual_JJ general_JJ meetings_NNS and_CC extraordinary_JJ Variation_NN of_IN these_DT borrowing_VBG powers_NNS would_MD general_JJ meetings_NNS where_WRB a_DT special_JJ resolution_NN require_VBP the_DT passing_NN of_IN a_DT special_JJ resolution_NN of_IN is_VBZ to_TO be_VB passed_VBN or_CC a_DT Director_NNP is_VBZ to_TO be_VB the_DT Companys_NNPS shareholders_NNS ._.
appointed_VBN require_VBP 21_CD clear_JJ days_NNS notice_VBP to_TO Designed_VBN by_IN Addison_NNP Corporate_NNP Marketing_NNP Ltd_NNP
